Evidence-Based Complementary and Alternative Medicine

Research Article

Improved Lipid Profile Associated with Daily Consumption of Tri-Sura-Phon in Healthy Overweight Volunteers: An Open-Label, Randomized Controlled Trial

Table 2

Effect of Tri-Sura-Phon tea drinking on body mass index, serum lipid profile, glucose and insulin levels, and liver function of healthy overweight volunteers.


Parameters	Tested group	Mean (SD)
Parameters	Tested group	Baseline	4th week	8th week

BMI (kg/m²)	Tri-Sura-Phon	27.7 (4.5)	27.6 (4.5)	27.6 (4.5)
BMI (kg/m²)	Placebo	28.3 (4.0)	28.0 (4.2)	28.2 (4.1)
Total cholesterol (mg/dL)	Tri-Sura-Phon	223.7 (37.6)	213.5 (29.2)	201.3 (36.2)
Total cholesterol (mg/dL)	Placebo	210.5 (33.0)	213.6 (37.2)	211.9 (42.6)
Triglycerides (mg/dL)	Tri-Sura-Phon	147.5 (74.3)³	79.3 (24.2)	103.4 (40.2)
Triglycerides (mg/dL)	Placebo	142.4 (75.9)	125.6 (61.5)	96.1 (37.5)
Low density lipoprotein (mg/dL)	Tri-Sura-Phon	130.5 (40.5)	129.7 (30.6)	108.5 (37.6)
Low density lipoprotein (mg/dL)	Placebo	116.2 (35.5)	125.0 (33.7)	131.7 (44.0)
High density lipoprotein (mg/dL)	Tri-Sura-Phon	63.4 (12.8)	68.0 (14.1)³	72.4 (13.4)
High density lipoprotein (mg/dL)	Placebo	65.8 (10.0)	67.6 (11.4)	60.9 (13.6)
FBG (mg/dL)	Tri-Sura-Phon	76.2 (6.1)^1,2,3	84.1 (7.9)	84.3 (8.4)
FBG (mg/dL)	Placebo	81.5 (12.0)	91.4 (12.8)	91.2 (9.0)
Insulin level (uU/mL)	Tri-Sura-Phon	8.9 (4.1)	8.3 (3.5)³	9.9 (5.0)
Insulin level (uU/mL)	Placebo	10.9 (7.0)	8.7 (4.2)	10.9 (7.0)
Albumin (gm/dL)	Tri-Sura-Phon	4.6 (0.5)²	4.5 (0.5)²	4.1 (0.5)
Albumin (gm/dL)	Placebo	4.5 (0.5)	4.1 (0.4)	4.6 (0.5)
Total bilirubin (mg/dL)	Tri-Sura-Phon	0.7 (0.4)	0.9 (0.3)³	0.8 (0.4)
Total bilirubin (mg/dL)	Placebo	0.8 (0.5)	0.9 (0.4)	0.6 (0.5)
Direct bilirubin (mg/dL)	Tri-Sura-Phon	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)
Direct bilirubin (mg/dL)	Placebo	0.0 (0.2)	0.0 (0.0)	0.0 (0.0)
AST (U/L)	Tri-Sura-Phon	20.1 (5.6)^2,3	22.6 (6.8)	19.8 (4.3)^2,3
AST (U/L)	Placebo	22.7 (7.1)	24.2 (5.1)	24.3 (13.2)
ALT (U/L)	Tri-Sura-Phon	21.1 (14.0)³	20.8 (13.4)³	18.7 (13.5)³
ALT (U/L)	Placebo	22.5 (11.6)	20.7 (11.1)	30.5 (26.5)
ALP (U/L)	Tri-Sura-Phon	78.1 (20.1)	76.0 (19.5)	69.6 (21.3)
ALP (U/L)	Placebo	77.5 (15.7)	74.8 (18.3)	74.5 (17.0)
GGT (U/L)	Tri-Sura-Phon	25.0 (15.7)	25.7 (16.0)	25.1 (17.7)
GGT (U/L)	Placebo	25.5 (8.6)	23.0 (8.3)	26.0 (12.2)

Uppercase superscript letters indicate the significant differences in parameters between the baseline and week 4 (A) or the baseline and week 8 (B) or weeks 4 and 8 (C) within the treatment.
Superscript numbers indicate the significant differences between the parameters at baseline (1), week 4 (2), or week 8 (3) among the treatments.
BMI = body mass index, FBG = fasting blood glucose, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, and GGT = gamma-glutamyl transpeptidase.